Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on March 1, 2004

Published online before print November 21, 2003
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.1003486v1
75/3/398    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bucala, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bucala, R.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.1003486

Received for publication October 18, 2003.

Accepted for publication October 21, 2003.

Article

Series introduction: molecular and cellular basis of septic shock

Rick Bucala @

The Anlyan Center, Department of Medicine and Pathology, Yale University School of Medicine, New Haven, Connecticut

@ To whom correspondence should be addressed. E-mail: richard.bucala{at}yale.edu.


  Abstract

This series of overviews was contributed by participants of a Keystone Symposium, which was convened in early 2003 to address the topic of septic shock in an interdisciplinary manner. This occasion reflects a resurgence of interest in septic shock as a disease that may soon be approachable by new therapeutic interventions.

Key Words: Toll-like receptor • immunomodulatory therapies • pharmacologic therapy






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2003 by the Society for Leukocyte Biology.